Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

In this article, we are going to take a look at where Erasca Inc. (NASDAQ ... its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace ...

Explore Erasca stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ERAS. e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling ...

Insiders who bought US$181.9k worth of Erasca, Inc.'s (NASDAQ:ERAS) stock at an average buy price of US$2.27 over the last year may be disappointed by the recent 11% decrease in the stock.

In a report released on March 28, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca (ERAS – Research Report). The company’s shares closed last Friday at $1.52. Discover the latest ...

Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has ...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has ...